

Prematurely ended - Statement

EudraCT Number: 2008-006055-52

Full title of the study: Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer.

Sponsor-ID: CRAD0019DE15T
Sponsor: Charité – Universitätsmedizin Berlin

Study Cotact: Professor Dr. med. Jan Eucker
Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie
jan.eucker@charite.de

Product: Carboplatin
Everolimus (RAD001) 2,5 mg and 5mg

Date of early termination: 2014/11/04

Statement:

The clinical trial was be early terminated because of insufficient recruiting in phase II. The planned number of patients (34) could not be achieved. So, the results could be used to confirm neither the efficacy nor the safety of, due to the inability to recruit a sufficient number of study subjects allowing statistical analysis. Accordingly, no conclusions could be drawn from the study.